Related Experiment Video
Updated: Jul 6, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Design and campaign synthesis of pyridine-based histone deacetylase inhibitors
David M Andrews1, Keith M Gibson, Mark A Graham
1Cancer and Infection Research, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. david.andrews@astrazeneca.com
Abstract:
A lead benzamide, bearing a cyanopyridyl moiety (3), was identified as a potent and low molecular weight histone deacetylase (HDAC) inhibitor. Various replacements of the cyano group were explored at the C3-position, along with the exploration of solubility-enhancing groups at the C5-position. It was determined that cyano substitution at the C3-position of the pyridyl core, along with a methylazetidinyl substituent at the C5-position yielded optimal HDAC1 inhibition and anti-proliferative activity in HCT-116 cells.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

